サマリー

欧州臨床試験市場調査レポート 2030年までの予測

市場概要
臨床試験件数の増加、臨床試験を実施するCRO（医薬品開発業務受託機関）に対する需要の高まり、強力な医療インフラは、欧州臨床試験市場を推進するいくつかの要因である。臨床試験のデジタル変革により、欧州の臨床試験業界には多くの成長機会があります。
臨床試験とは、生物医学的または行動学的介入に関する特定の疑問に答えるためにデザインされた、ヒト参加型の前向き生物医学的または行動学的研究であり、新たな治療法や、追加研究や比較が必要であると認識されている介入を含む。
欧州臨床試験市場の成長は、臨床試験数の増加と強力な医療インフラに起因している。加えて、臨床試験のデジタル化、疾病の増加、欧州医薬品庁（EMA）による新規活性物質の承認の増加が、今後の市場に成長機会をもたらすだろう。しかし、熟練した経験豊富な専門家の不足は、予測期間における市場の成長を妨げる可能性がある。
市場区分
フェーズに基づき、欧州臨床試験市場はフェーズI、フェーズII、フェーズIII、フェーズIVに区分される。
試験デザインに基づき、欧州臨床試験市場は観察、介入、拡大アクセスに区分される。
アプリケーションに基づき、欧州臨床試験市場は医薬品、医療機器、栄養、その他に区分される。
サービスタイプ別に見ると、欧州臨床試験市場はプロトコール設計、施設特定、患者募集、ラボサービス、生物分析試験サービス、臨床試験データ管理サービス、その他に区分される。
エンドユーザー別に見ると、欧州臨床試験市場は製薬・バイオテクノロジー企業、医療機器企業、学術・研究機関、栄養補助食品企業に区分される。
欧州臨床試験市場には、ドイツ、フランス、英国、イタリア、スペイン、オーストリア、その他の欧州諸国が含まれる。欧州臨床試験市場は、その成長と発展に寄与するいくつかの重要な要因によって牽引されている。以下に挙げる要因は、欧州臨床試験市場の全体的な地域動向と一致している。
主要企業
IQVIA (米国)、Laboratory Corporation of America Holdings (米国)、ICON PLC (アイルランド)、PPD Inc (米国)、Syneos Health (米国)、CTI Clinical Trial and Consulting (米国)、Medpace Inc (米国)、Charles River Laboratories (米国)、Parexel International (MA) Corporation (米国)、Antaea Medical Services Ltd (ギリシャ)。

ページTOPに戻る

目次

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 13
1.1 OVERVIEW 13
2 MARKET INTRODUCTION 14
2.1 DEFINITION 14
2.2 SCOPE OF THE STUDY 14
2.3 RESEARCH OBJECTIVE 14
2.4 MARKET STRUCTURE 15
2.5 LIST OF ASSUMPTIONS 16
3 RESEARCH METHODOLOGY 17
3.1 OVERVIEW 17
3.2 DATA MINING 17
3.3 SECONDARY RESEARCH 18
3.4 PRIMARY RESEARCH 19
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 20
3.5 FORECASTING TECHNIQUES 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 22
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 23
3.8 VALIDATION 23
4 MARKET DYNAMICS 24
4.1 OVERVIEW 24
4.2 DRIVERS 25
4.2.1 INCREASING NUMBER OF CLINICAL TRIALS 25
4.2.2 STRONG HEALTHCARE INFRASTRUCTURE 25
4.3 RESTRAINTS 27
4.3.1 SHORTAGE OF SKILLED AND EXPERIENCED PROFESSIONALS 27
4.4 OPPORTUNITY 27
4.4.1 DIGITAL TRANSFORMATION IN CLINICAL TRIALS 27
4.4.2 GROWING INCIDENCES OF DISEASES 28
4.4.3 INCREASING APPROVAL OF NEW ACTIVE SUBSTANCES BY EUROPE MEDICINE AGENCY(EMA) 29
5 MARKET FACTOR ANALYSIS 30
5.1 VALUE CHAIN ANALYSIS 30
5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY) 31
5.1.2 SERVICE CUSTOMIZATION 31
5.1.3 CUSTOMER PURCHASE SUPPORT 31
5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT 31
5.2 PORTER'S FIVE FORCES MODEL 32
5.2.1 THREAT OF NEW ENTRANTS 32
5.2.2 BARGAINING POWER OF SUPPLIERS 33
5.2.3 THREAT OF SUBSTITUTES 33
5.2.4 BARGAINING POWER OF BUYERS 33
5.2.5 INTENSITY OF RIVALRY 33
5.3 IMPACT OF COVID-19 ON EUROPE CLINICAL TRIAL MARKET 34
5.3.1 OVERVIEW 34
5.3.2 IMPACT ON PRICING 34
5.3.3 IMPACT ON KEY PLAYERS 34
5.4 LIST OF DRUGS AND DEVICES MANUFACTURERS PRESENCE IN EUROPE 35
6 EUROPE CLINICAL TRIALS MARKET, BY PHASE 37
6.1 OVERVIEW 37
6.2 PHASE I 39
6.3 PHASE II 40
6.3.1 PHASE IIA 40
6.3.2 PHASE IIB ERROR! BOOKMARK NOT DEFINED.
6.4 PHASE III 41
6.5 PHASE IV 42
7 EUROPE CLINICAL TRIALS MARKET, BY STUDY DESIGN 43
7.1 OVERVIEW 43
7.2 OBSERVATIONAL 45
7.3 INTERVENTIONAL 46
7.4 EXPANDED ACCESS 46
8 EUROPE CLINICAL TRIALS MARKET, BY APPLICATION 47
8.1 OVERVIEW 47
8.2 PHARMACEUTICAL 49
8.2.1 NEUROLOGICAL 50
8.2.2 ONCOLOGY 51
8.2.3 CARDIOVASCULAR 51
8.2.4 INFECTIOUS DISEASES 52
8.2.5 OTHERS 52
8.3 MEDICAL DEVICES 53
8.4 NUTRITION 53
8.5 OTHERS 54
9 EUROPE CLINICAL TRIALS MARKET, BY SERVICE TYPE 55
9.1 OVERVIEW 55
9.2 PROTOCOL DESIGNING 58
9.3 SITE IDENTIFICATION 58
9.4 PATIENT RECRUITMENT 59
9.5 LABORATORY SERVICES 59
9.6 BIOANALYTICAL TESTING SERVICES 60
9.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES 60
9.8 OTHERS 61
10 EUROPE CLINICAL TRIALS MARKET, BY END USER 62
10.1 OVERVIEW 62
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 64
10.3 MEDICAL DEVICE COMPANIES 65
10.4 ACADEMIC & RESEARCH INSTITUTES 65
10.5 NUTRACEUTICAL COMPANIES 66
11 EUROPE CLINICAL TRIALS MARKET, BY COUNTRY 67
11.1 OVERVIEW 67
11.1.1 GERMANY 71
11.1.2 FRANCE 74
11.1.3 UK 76
11.1.4 ITALY 79
11.1.5 SPAIN 81
11.1.6 AUSTRIA 84
11.1.7 REST OF EUROPE 86
12 COMPETITIVE LANDSCAPE 89
12.1 OVERVIEW 89
12.2 COMPETITIVE BENCHMARKING 90
12.3 MAJOR GROWTH STRATEGY IN THE EUROPE CLINICAL TRIALS MARKET 91
12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE EUROPE CLINICAL TRIALS MARKET 91
12.5 KEY DEVELOPMENT ANALYSIS 92
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 92
12.6.1 SERVICE LAUNCH 92
12.6.2 MERGER/ACQUISITION 93
12.6.3 PARTNERSHIP/COLLABOARTION/AGREEMENT/EXPANSION/INVESTMENT 93
12.7 FINANCIAL MATRIX 94
12.7.1 SALES (USD MILLION), 2022 94
12.7.2 MARGINS FROM SERVICES OFFERED FOR CLINICAL STUDIES IN THE MEDICAL DEVICE AND PHARMACEUTICAL AREA 94
12.7.3 TURNOVER OF CROS WORLDWIDE, EUROPE-WIDE, AND GERMANY AND AUSTRIA 95
13.1 CHARLES RIVER LABORATORIES 96
13.1.1 COMPANY OVERVIEW 96
13.1.2 FINANCIAL OVERVIEW 97
13.1.3 SERVICES OFFERED 98
13.1.4 KEY DEVELOPMENTS 98
13.1.5 SWOT ANALYSIS 99
13.1.6 KEY STRATEGIES 99
13.2 PAREXEL INTERNATIONAL (MA) CORPORATION 100
13.2.1 COMPANY OVERVIEW 100
13.2.2 FINANCIAL OVERVIEW 100
13.2.3 SERVICES OFFERED 100
13.2.4 KEY DEVELOPMENTS 100
13.2.5 KEY STRATEGIES 101
13.3 ICON PLC 102
13.3.1 COMPANY OVERVIEW 102
13.3.2 FINANCIAL OVERVIEW 103
13.3.3 SERVICES OFFERED 103
13.3.4 KEY DEVELOPMENTS 104
13.3.5 SWOT ANALYSIS 105
13.3.6 KEY STRATEGIES 105
13.4 LABORATORY CORPORATION OF AMERICA HOLDINGS 106
13.4.1 COMPANY OVERVIEW 106
13.4.2 FINANCIAL OVERVIEW 107
13.4.3 SERVICES OFFERED 107
13.4.4 KEY DEVELOPMENTS 108
13.4.5 SWOT ANALYSIS 108
13.4.6 KEY STRATEGIES 108
13.5 PPD INC 109
13.5.1 COMPANY OVERVIEW 109
13.5.2 FINANCIAL OVERVIEW 109
13.5.3 SERVICES OFFERED 109
13.5.4 KEY DEVELOPMENTS 110
13.5.5 SWOT ANALYSIS 111
13.5.6 KEY STRATEGIES 111
13.6 SYNEOS HEALTH 112
13.6.1 COMPANY OVERVIEWS 112
13.6.2 FINANCIAL OVERVIEW 113
13.6.3 SERVICES OFFERED 114
13.6.4 KEY DEVELOPMENTS 114
13.6.5 KEY STRATEGIES 114
13.7 CTI CLINICAL TRIAL & CONSULTING 115
13.7.1 COMPANY OVERVIEW 115
13.7.2 FINANCIAL OVERVIEW 115
13.7.3 SERVICES OFFERED 115
13.7.4 KEY DEVELOPMENTS 116
13.7.5 KEY STRATEGIES 116
13.8 IQVIA 117
13.8.1 COMPANY OVERVIEW 117
13.8.2 FINANCIAL OVERVIEW 118
13.8.3 SERVICES OFFERED 119
13.8.4 KEY DEVELOPMENTS 119
13.8.5 SWOT ANALYSIS 119
13.8.6 KEY STRATEGIES 119
13.9 MEDPACE INC 120
13.9.1 COMPANY OVERVIEW 120
13.9.2 FINANCIAL OVERVIEW 121
13.9.3 SERVICES OFFERED 122
13.9.4 KEY DEVELOPMENTS 122
13.9.5 KEY STRATEGIES 122
13.10 ANTAEA MEDICAL SERVICES LTD. 123
13.10.1 COMPANY OVERVIEW 123
13.10.2 FINANCIAL ANALYSIS 123
13.10.3 SERVICES OFFERED 123
13.10.4 KEY DEVELOPMENTS 123
13.10.5 KEY STRATEGIES 123
14 APPENDIX 124
14.1 REFERENCES 124
14.2 RELATED REPORTS 124
 

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16
TABLE 2 DIABETES ESTIMATES (20-79 YEARS) FOR 2021, 2030, AND 2045 28
TABLE 3 CHILDREN & ADOLESCENTS AND ADULTS WITH OBESITY IN 2020, 2025, 2030, AND 2035 28
TABLE 4 LIST OF MEDICAL DEVICE MANUFACTURERS 35
TABLE 5 LIST OF DRUGS MANUFACTURERS 36
TABLE 6 EUROPE CLINICAL TRIALS MARKET, FOR PHASE, BY COUNTRY, 2019–2030 (USD MILLION) 38
TABLE 7 EUROPE CLINICAL TRIALS MARKET, FOR PHASE I, BY COUNTRY, 2019–2030 (USD MILLION) 39
TABLE 8 EUROPE CLINICAL TRIALS MARKET, FOR PHASE II, BY COUNTRY, 2019–2030 (USD MILLION) 40
TABLE 9 EUROPE CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION) 40
TABLE 10 EUROPE CLINICAL TRIALS MARKET, FOR PHASE IIA, BY COUNTRY, 2019–2030 (USD MILLION) 40
TABLE 11 EUROPE CLINICAL TRIALS MARKET, FOR PHASE IIB, BY COUNTRY, 2019–2030 (USD MILLION) 41
TABLE 12 EUROPE CLINICAL TRIALS MARKET, FOR PHASE III, BY COUNTRY, 2019–2030 (USD MILLION) 41
TABLE 13 EUROPE CLINICAL TRIALS MARKET, FOR PHASE III, BY COUNTRY, 2019–2030 (USD MILLION) 42
TABLE 14 EUROPE CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION) 44
TABLE 15 EUROPE CLINICAL TRIALS MARKET, FOR OBSERVATIONAL, BY COUNTRY, 2019–2030 (USD MILLION) 45
TABLE 16 EUROPE CLINICAL TRIALS MARKET, FOR INTERVENTIONAL, BY COUNTRY, 2019–2030 (USD MILLION) 46
TABLE 17 EUROPE CLINICAL TRIALS MARKET, FOR EXPANDED ACCESS, BY COUNTRY, 2019–2030 (USD MILLION) 46
TABLE 18 EUROPE CLINICAL TRIALS MARKET, FOR APPLICATION, BY COUNTRY, 2019–2030 (USD MILLION) 48
TABLE 19 EUROPE CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY COUNTRY, 2019–2030 (USD MILLION) 49
TABLE 20 EUROPE CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION) 50
TABLE 21 EUROPE CLINICAL TRIALS MARKET, FOR NEUROLOGICAL, BY COUNTRY, 2019–2030 (USD MILLION) 50
TABLE 22 EUROPE CLINICAL TRIALS MARKET, FOR ONCOLOGY, BY COUNTRY, 2019–2030 (USD MILLION) 51
TABLE 23 EUROPE CLINICAL TRIALS MARKET, FOR CARDIOVASCULAR, BY COUNTRY, 2019–2030 (USD MILLION) 51
TABLE 24 EUROPE CLINICAL TRIALS MARKET, FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2030 (USD MILLION) 52
TABLE 25 EUROPE CLINICAL TRIALS MARKET, FOR OTHERS, BY COUNTRY, 2019–2030 (USD MILLION) 52
TABLE 26 EUROPE CLINICAL TRIALS MARKET, FOR MEDICAL DEVICES, BY COUNTRY, 2019–2030 (USD MILLION) 53
TABLE 27 EUROPE CLINICAL TRIALS MARKET, FOR NUTRITION, BY COUNTRY, 2019–2030 (USD MILLION) 53
TABLE 28 EUROPE CLINICAL TRIALS MARKET, FOR OTHERS, BY COUNTRY, 2019–2030 (USD MILLION) 54
TABLE 29 EUROPE CLINICAL TRIALS MARKET, BY SERVICE TYPE 2019–2030 (USD MILLION) 57
TABLE 30 EUROPE CLINICAL TRIALS MARKET, FOR PROTOCOL DESIGNING, BY COUNTRY, 2019–2030 (USD MILLION) 58
TABLE 31 EUROPE CLINICAL TRIALS MARKET, FOR SITE IDENTIFICATION, BY COUNTRY, 2019–2030 (USD MILLION) 58
TABLE 32 EUROPE CLINICAL TRIALS MARKET, FOR PATIENT RECRUITMENT, BY COUNTRY, 2019–2030 (USD MILLION) 59
TABLE 33 EUROPE CLINICAL TRIALS MARKET, FOR LABORATORY SERVICES, BY COUNTRY, 2019–2030 (USD MILLION) 59
TABLE 34 EUROPE CLINICAL TRIALS MARKET, FOR BIOANALYTICAL TESTING SERVICES, BY COUNTRY, 2019–2030 (USD MILLION) 60
TABLE 35 EUROPE CLINICAL TRIALS MARKET, FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY COUNTRY, 2019–2030 (USD MILLION) 60
TABLE 36 EUROPE CLINICAL TRIALS MARKET, FOR OTHERS, BY COUNTRY, 2019–2030 (USD MILLION) 61
TABLE 37 EUROPE CLINICAL TRIALS MARKET, FOR END USER, BY COUNTRY, 2019–2030 (USD MILLION) 63
TABLE 38 EUROPE CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2030 (USD MILLION) 64
TABLE 39 EUROPE CLINICAL TRIALS MARKET, FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2030 (USD MILLION) 65
TABLE 40 EUROPE CLINICAL TRIALS MARKET, FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2030 (USD MILLION) 65
TABLE 41 EUROPE CLINICAL TRIALS MARKET, FOR NUTRACEUTICAL COMPANIES, BY COUNTRY, 2019–2030 (USD MILLION) 66
TABLE 42 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2030 (USD MILLION) 70
TABLE 43 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION) 71
TABLE 44 GERMANY: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION) 71
TABLE 45 GERMANY: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION) 72
TABLE 46 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION) 72
TABLE 47 GERMANY: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION) 72
TABLE 48 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION) 73
TABLE 49 GERMANY: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION) 73
TABLE 50 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION) 74
TABLE 51 FRANCE: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION) 74
TABLE 52 FRANCE: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION) 74
TABLE 53 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION) 75
TABLE 54 FRANCE: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION) 75
TABLE 55 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION) 75
TABLE 56 FRANCE: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION) 76
TABLE 57 UK: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION) 76
TABLE 58 UK: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION) 76
TABLE 59 UK: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION) 77
TABLE 60 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION) 77
TABLE 61 UK: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION) 77
TABLE 62 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION) 78
TABLE 63 UK: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION) 78
TABLE 64 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION) 79
TABLE 65 ITALY: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION) 79
TABLE 66 ITALY: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION) 79
TABLE 67 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION) 80
TABLE 68 ITALY: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION) 80
TABLE 69 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION) 80
TABLE 70 ITALY: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION) 81
TABLE 71 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION) 81
TABLE 72 SPAIN: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION) 81
TABLE 73 SPAIN: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION) 82
TABLE 74 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION) 82
TABLE 75 SPAIN: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION) 82
TABLE 76 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION) 83
TABLE 77 SPAIN: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION) 83
TABLE 78 AUSTRIA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION) 84
TABLE 79 AUSTRIA: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION) 84
TABLE 80 AUSTRIA: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION) 84
TABLE 81 AUSTRIA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION) 85
TABLE 82 AUSTRIA: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION) 85
TABLE 83 AUSTRIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION) 85
TABLE 84 AUSTRIA: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION) 86
TABLE 85 REST OF EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION) 86
TABLE 86 REST OF EUROPE: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION) 86
TABLE 87 REST OF EUROPE: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION) 87
TABLE 88 REST OF EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION) 87
TABLE 89 REST OF EUROPE: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION) 87
TABLE 90 REST OF EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION) 88
TABLE 91 REST OF EUROPE: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION) 88
TABLE 92 MAJOR PLAYERS IN THE EUROPE CLINICAL TRIALS MARKET 89
TABLE 93 MOST ACTIVE PLAYER IN THE EUROPE CLINICAL TRIALS MARKET 91
TABLE 94 SERVICE LAUNCH 92
TABLE 95 MERGER/ACQUISITION 93
TABLE 96 PARTNERSHIP/COLLABOARTION/AGREEMENT/EXPANSION/INVESTMENT 93
TABLE 97 MARGINS FROM SERVICES OFFERED FOR CLINICAL STUDIES IN THE MEDICAL DEVICE AND PHARMACEUTICAL AREA, 2022-2023 94
TABLE 98 CHARLES RIVER LABORATORIES: SERVICES OFFERED 98
TABLE 99 PAREXEL INTERNATIONAL (MA) CORPORATION: SERVICES OFFERED 100
TABLE 100 ICON PLC: SERVICES OFFERED 103
TABLE 101 ICON PLC: KEY DEVELOPMENTS 104
TABLE 102 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED 107
TABLE 103 PPD INC: SERVICES OFFERED 109
TABLE 104 PPD INC: KEY DEVELOPMENTS 110
TABLE 105 SYNEOS HEALTH: SERVICES OFFERED 114
TABLE 106 SYNEOS HEALTH: KEY DEVELOPMENTS 114
TABLE 107 CTI CLINICAL TRIAL & CONSULTING: SERVICES OFFERED 115
TABLE 108 IQVIA: SERVICES OFFERED 119
TABLE 109 MEDPACE INC: SERVICES OFFERED 122
TABLE 110 ANTAEA MEDICAL SERVICES LTD: SERVICES OFFERED 123